Related Experiment Videos
Developmental aspects of percutaneous caffeine absorption in premature infants
M Amato1, P Hüppi, M Isenschmid
1Department of Obstetrics and Gynecology, University of Berne, Switzerland.
Insights
Caffeine treatment for apnea of prematurity shows varying skin absorption in preterm infants. Younger infants with lower gestational age absorb more caffeine through the skin, aiding understanding of newborn skin barrier function.
Area of Science:
- Neonatalogy
- Pharmacokinetics
- Dermatology
Background:
- Caffeine is a standard treatment for apnea of prematurity.
- Preterm infant skin maturity varies significantly, impacting drug absorption.
- Understanding percutaneous absorption is crucial for optimizing neonatal care.
Purpose of the Study:
- To investigate caffeine skin absorption in low birthweight infants.
- To correlate gestational age and birthweight with caffeine absorption.
- To enhance understanding of the neonatal skin barrier's role in drug delivery.
Main Methods:
- Studied 56 preterm infants (gestational age 26-34 weeks, birthweight <1500 gm).
- Administered caffeine percutaneously (7.5 mg or 10 mg twice daily based on birthweight).
- Analyzed the relationship between infant characteristics and caffeine absorption.
Main Results:
- Observed significant variation in skin absorption levels among preterm infants.
- Found an inverse relationship between gestational age and caffeine skin absorption.
- Demonstrated that percutaneous caffeine administration is a viable method for premature infants.
Conclusions:
- Gestational age is a key factor influencing neonatal skin absorption of caffeine.
- Results provide insights into the functional development of the newborn skin barrier.
- Percutaneous drug administration offers a practical alternative for treating apnea of prematurity.
Abstract:
Caffeine is commonly used in the treatment of apnea of prematurity. The skin of preterm infants varies considerably in its level of maturity. To understand skin absorption in low birthweight infants (less than 1500 gm) with gestational age between 26 and 34 weeks, a group of 56 preterm babies was studied after percutaneous application of 7.5 mg twice daily of caffeine for babies with birthweight less than 1000 gm and 10 mg twice daily for babies with birthweight more than 1000 gm. The reported technique is a useful alternative method of drug administration in premature babies. This study indicates an inverse relationship between gestational age and skin absorption contributing to a better understanding of skin barrier function in the newborn.